To evaluate if patients with Ehlers–Danlos syndromes (EDS) are at an increased risk for gynecologic and obstetric diagnoses compared with age-matched patients without EDS.
Methods:
We conducted a retrospective cohort study using the TriNetX research network. The study included female patients aged 18–44: there were 50,809 patients per cohort after matching for age. The risk of 18 gynecologic diagnoses and 6 obstetric diagnoses were assessed between the cohorts based on ICD-10 coding.
Results:
Patients with EDS were at an elevated risk for almost all the diagnoses assessed. The greatest increase in risk was seen for urogynecologic conditions. These patients were also at an increased risk for benign gynecologic diagnoses, adverse obstetric outcomes, and they received more fertility care.
Conclusion:
Using a large database, we were able to validate prior studies that assessed a limited number of conditions, our work expands on the conditions EDS patients may encounter.
MalfaitF, FrancomanoC, ByersP, et al.The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet, 2017; 175(1):8–26.
3.
SorokinY, JohnsonMP, RogowskiN, et al.Obstetric and gynecologic dysfunction in the Ehlers-Danlos syndrome. J Reprod Med, 1994; 39(4):281–284.
4.
HurstBS, LangeSS, KullstamSM, et al.Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome. Obstet Gynecol, 2014; 123(3):506–513.
5.
BlagowidowN. Obstetrics and gynecology in Ehlers-Danlos syndrome: A brief review and update. Am J Med Genet C Semin Med Genet, 2021; 187(4):593–598.
6.
GilliamE, HoffmanJD, YehG. Urogenital and pelvic complications in the Ehlers-Danlos syndromes and associated hypermobility spectrum disorders: A scoping review. Clin Genet, 2020; 97(1):168–178.
7.
JesseN, YunkerA. Prevalence of endometriosis and pelvic pain in patients with hereditary connective tissue disorders. Am J Obstet Gynecol, 2024; 230(4):S1198–S1199.
8.
McIntoshLJ, MallettVT, FrahmJD, et al.Gynecologic disorders in women with Ehlers-Danlos syndrome. J Soc Gynecol Investig, 1995; 2(3):559–564.
9.
BonglackM, HoehnJ, RayMM, et al.Pelvic floor disorders in Ehlers Danlos syndrome compared to control population. Discov Med, 2025; 2(1):155.
10.
SpiegelE, Nicholls-DempseyL, Czuzoj-ShulmanN, et al.Pregnancy outcomes in women with Ehlers-Danlos Syndrome. J Matern Fetal Neonatal Med, 2022; 35(9):1683–1689.
11.
AlrifaiN, AlhuneafatL, JabriA, et al.Pregnancy and fetal outcomes in patients with Ehlers-Danlos syndrome: A nationally representative analysis. Curr Probl Cardiol, 2023; 48(7):101634.
12.
CheulotP, SaucedoM, Bouvier-ColleMH, et al.; pour le Comité national d’experts sur la mortalité maternelle. [Maternal mortality among women with Marfan syndrome or vascular Ehlers-Danlos syndrome in France, 2001–2012]. Gynecol Obstet Fertil Senol, 2019; 47(1):30–35.
13.
KoitabashiN, YamaguchiT, FukuiD, et al.Peripartum iliac arterial aneurysm and rupture in a patient with vascular Ehlers-Danlos syndrome diagnosed by next-generation sequencing. Int Heart J, 2018; 59(5):1180–1185.
14.
VanakkerO, CallewaertB, MalfaitF, et al.The genetics of soft connective tissue disorders. Annu Rev Genomics Hum Genet, 2015; 16:229–255.
15.
PalchukMB, LondonJW, Perez-ReyD, et al.A global federated real-world data and analytics platform for research. JAMIA Open, 2023; 6(2):ooad035.
16.
KatonJG, PlowdenTC, MarshEE. Racial disparities in uterine fibroids and endometriosis: A systematic review and application of social, structural, and political context. Fertil Steril, 2023; 119(3):355–363.
17.
CatherinoWH, EltoukhiHM, Al-HendyA. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med, 2013; 31(5):370–379.
18.
GlayzerJE, McFarlinBL, CastoriM, et al.High rate of dyspareunia and probable vulvodynia in Ehlers–Danlos syndromes and hypermobility spectrum disorders: An online survey. Am J Med Genet C Semin Med Genet, 2021; 187(4):599–608.
19.
Hugon-RodinJ, LebègueG, BecourtS, et al.Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type Ehlers-Danlos syndrome: A cohort study. Orphanet J Rare Dis, 2016; 11(1):124.
20.
CastoriM, MorlinoS, DordoniC, et al.Gynecologic and obstetric implications of the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome hypermobility type) in 82 Italian patients. Am J Med Genet A, 2012; 158A(9):2176–2182.
21.
CarleyME, SchafferJ. Urinary incontinence and pelvic organ prolapse in women with Marfan or Ehlers Danlos syndrome. Am J Obstet Gynecol, 2000; 182(5):1021–1023.
22.
NazemiA, ShapiroK, NagpalS, et al.Pelvic organ prolapse in Ehlers-Danlos syndrome. Case Rep Urol, 2023; 2023:6863711.
23.
ReychlerG, De BackerM-M, PirauxE, et al.Physical therapy treatment of hypermobile Ehlers-Danlos syndrome: A systematic review. Am J Med Genet A, 2021; 185(10):2986–2994.
24.
EngelbertRHH, Juul-KristensenB, PaceyV, et al.The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. Am J Med Genet C Semin Med Genet, 2017; 175(1):158–167.
25.
DavidsonERW, AlamPA, ByrnesJN, et al.Perioperative outcomes following pelvic floor reconstruction in women with hereditary disorders of connective tissue: A retrospective cohort study. Int Urogynecol J, 2021; 32(8):2135–2142.
26.
HurstBS, LangMB, KullstamSM, et al.Reproductive challenges in women with Ehlers-Danlos syndrome: Survey results from over 1350 respondents from the Ehlers-Danlos national foundation. Fertil Steril, 2012; 98(3):S112.
27.
De WandeleI, CaldersP, PeersmanW, et al.Autonomic symptom burden in the hypermobility type of Ehlers–Danlos syndrome: A comparative study with two other EDS types, fibromyalgia, and healthy controls. Semin Arthritis Rheum, 2014; 44(3):353–361.
28.
MathiasCJ, OwensA, IodiceV, et al.Dysautonomia in the Ehlers-Danlos syndromes and hypermobility spectrum disorders-with a focus on the postural tachycardia syndrome. Am J Med Genet C Semin Med Genet, 2021; 187(4):510–519.
29.
AngwinC, GhaliN, van DijkFS. Case report and discussion: Pre-implantation genetic diagnosis with surrogacy in vascular Ehlers–Danlos syndrome. Front Genet, 2023; 14:1147607.
30.
BergeronM-E, ChildT, FatumM. In vitro maturation and surrogacy in patients with vascular-type Ehlers-Danlos syndrome–a safe assisted reproductive technology approach. Hum Fertil (Camb), 2014; 17(2):141–144.
31.
MurrayML, PepinM, PetersonS, et al.Pregnancy-related deaths and complications in women with vascular Ehlers–Danlos syndrome. Genet Med, 2014; 16(12):874–880.
32.
PearceG, BellL, PezaroS, et al.Childbearing with hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders: A large international survey of outcomes and complications. Int J Environ Res Public Health, 2023; 20(20):6957.
33.
MonacoA, ChoiD, UzunS, et al.Association of mast-cell-related conditions with hypermobile syndromes: A review of the literature. Immunol Res, 2022; 70(4):419–431.
34.
RoyerSP, HanSJ. Mechanobiology in the comorbidities of Ehlers Danlos syndrome. Front Cell Dev Biol, 2022; 10:874840; doi: 10.3389/fcell.2022.874840
35.
DorffSR, AfrinLB. Mast cell activation syndrome in pregnancy, delivery, postpartum and lactation: A narrative review. J Obstet Gynaecol, 2020; 40(7):889–901.
